whitepaper

App Note: Comparability Study of Manual and Automated Particle Characterization with MFI

Posted: 11 October 2015 |

In collaboration with Takeda, Micro-Flow Imaging with the Bot1 Autosampler automated manual methods for monitoring biopharmaceutical quality/safety…

Micro-Flow Imaging (MFI) has become a standard application for particle analysis of protein formulations because of its ability to easily detect particle size and morphology for a diverse range of particle contaminants, including translucent protein fragments and silicone micro-droplets.

Recently, the US Pharmacopeial Convention proposed changes to the USP <787> standard, recommending the use of particle morphology detection through technologies such as Micro-Flow Imaging for sub-visible particle characterization.

Higher throughput and standardization are needed to meet the demand for biopharmaceutical testing of sub-visible particle characterization. The MFI 5000 series instruments can be automated with the addition of the Bot1 autosampler which reduces the hands-on time for sample evaluation. Because the automated mode requires a different sample presentation, the method parameters are often modified in order to provide the same results in automated mode as it does in manual mode. Here we outline the process for transferring a manual protocol to an automated format with the Bot1 autosampler and the MFI 5000 series, with regard to sample volume and mixing parameters.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

To demonstrate the comparability of running the MFI system in manual and automated modes, we ran a model protein system comprised of 1% BSA at multiple sites. Each sample was run at least eight times in both the manual and automated modes at two different laboratories. No statistically relevant differences were observed between manual and automated runs at either facility.

This application note is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here